Bausch Health Companies Inc. (TSX:BHC)
| Market Cap | 3.26B |
| Revenue (ttm) | 13.97B |
| Net Income (ttm) | 504.23M |
| Shares Out | n/a |
| EPS (ttm) | 1.35 |
| PE Ratio | 6.47 |
| Forward PE | 1.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 566,003 |
| Average Volume | 434,010 |
| Open | 9.11 |
| Previous Close | 9.27 |
| Day's Range | 8.77 - 9.14 |
| 52-Week Range | 5.91 - 12.44 |
| Beta | 0.40 |
| RSI | 44.97 |
| Earnings Date | Oct 29, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
John Paulson's hedge fund boosts Bausch Health, trims Madrigal in Q3 moves
John Paulson's Strategic Move: Significant Increase in Bausch Health Companies Inc.
John Paulson's Strategic Move: Significant Increase in Bausch Health Companies Inc.
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical
Bausch + Lomb CEO Brent Saunders joins 'Squawk Box' to preview the company's investor day, details of the company's three-year plan for profitable growth, impact of tariffs, and more.
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter ...
Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path
Bausch Health exceeds Q3 expectations. Explore BHC's 36.8% upside, debt reduction strategy, and key risks.
Will Bausch (BHC) Gain on Rising Earnings Estimates?
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch Health (BHC) Expands OraPharma into Canada and Puerto Rico
Bausch Health (BHC) Expands OraPharma into Canada and Puerto Rico
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2...
Bausch + Lomb to Hold Investor Day on Nov. 13
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on T...
Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results
Bausch Health Companies delivered strong Q3 results, with revenue up 6.8% year-over-year and EPS beating estimates by $0.10. BHC's growth is driven by successful product launches like Cabtreo, robust ...
Bausch Health (BHC) Q3 2025 Earnings Transcript
Bausch Health (BHC) Q3 2025 Earnings Transcript
Bausch Health Companies Inc (BHC) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Bausch Health Companies Inc (BHC) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt Reduction
Q3 2025 Bausch Health Companies Inc Earnings Call Transcript
Q3 2025 Bausch Health Companies Inc Earnings Call Transcript
BHC December 12th Options Begin Trading
Investors in Bausch Health Companies Inc (Symbol: BHC) saw new options become available today, for the December 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down...
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Bausch Health (BHC) Sees Growth and Raises Financial Guidance
Bausch Health (BHC) Sees Growth and Raises Financial Guidance
Bausch Health Companies Turns To Profit In Q3; Stock Up In After-hours
(RTTNews) - Bausch Health Companies Inc. (BHC, BHC.TO) reported that its net income attributable to the company for the third quarter of 2025 was $179 million or $0.48 per share, compared to net loss ...
Bausch Health Companies Inc. 2025 Q3 - Results - Earnings Call Presentation
Bausch Health raises 2025 revenue guidance to $5B-$5.1B while strengthening Solta and Salix growth
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
Bausch Health Companies Inc. ( BHC) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Garen Sarafian - VP & Head of Investor Relations Thomas Appio - CEO & Director Jean-Jacques...
Bausch Health (BHC) Boosts Outlook; Shares Surge After Hours
Bausch Health (BHC) Boosts Outlook; Shares Surge After Hours
Bausch Health (BHC) Reports Strong Q3 Results and Strategic Expansion
Bausch Health (BHC) Reports Strong Q3 Results and Strategic Expansion
Bausch Health (BHC) Exceeds Q3 Earnings and Revenue Expectations
Bausch Health (BHC) Exceeds Q3 Earnings and Revenue Expectations
Bausch Health rises on 2025 revenue, EBITDA guidance boost, Q3 beats
Bausch Health Exceeds Q3 Expectations with $0.48 EPS and $2.68 Billion Revenue
Bausch Health Exceeds Q3 Expectations with $0.48 EPS and $2.68 Billion Revenue